Table 1.
Patient Characteristics and Data
| Age (years) | 58.5 [52–68] |
| Female sex | 6 (25.0) |
| BMI (kg/m2) | 26.3 [23.3–28.0] |
| Drinking history | 13 (54.2) |
| Smoking | 13 (54.2) |
| DCM | 9 (37.5) |
| HCM | 10 (41.7) |
| Sarcoidosis | 3 (12.5) |
| Hypertension | 13 (54.2) |
| Untreated hypertension | 2 (8.3) |
| Diabetes | 9 (37.5) |
| CAD | 0 (0.0) |
| COPD | 1 (4.2) |
| Stroke | 1 (4.2) |
| Anemia | 2 (8.3) |
| CKD | 7 (29.2) |
| VT | 4 (16.7) |
| Atrial fibrillation | 3 (12.5) |
| LVAD | 1 (4.2) |
| Valve surgery | 2 (8.3) |
| Laboratory data | |
| WBC (/μL) | 5,950 [4,950.0–7,375.0] |
| Lymphocytes (%) | 32.4 [20.5–37.8] |
| Hemoglobin (g/dL) | 14.7 [13.8–15.4] |
| Platelets (×104/μL) | 18.9 [15.8–21.7] |
| Total protein (g/dL) | 7.2 [6.9–7.7] |
| Albumin (g/dL) | 4.2 [4.0–4.5] |
| Total bilirubin (mg/dL) | 0.80 [0.60–1.1] |
| NT-proBNP (pg/mL) | 1,260.0 [388.0–1,966.5] |
| eGFR (mL/min/1.73 m2) | 62.7 [52.5–73.7] |
| hs-TNT (ng/mL) | 0.016 [0.011–0.033] |
| HbA1c (%) | 6.2 [5.7–6.5] |
| Creatine kinase (U/L) | 80.5 [63.8–162.3] |
| CRP (mg/dL) | 0.09 [0.04–0.19] |
| Echocardiography | |
| IVST (mm) | 11.5 [9.0–17.3] |
| PWT (mm) | 11.0 [8.3–12.0] |
| LVDd (mm) | 53.5 [41.5–64.3] |
| LVDs (mm) | 33.0 [25.0–56.0] |
| LVEF (%) | 45.0 [27.3–72.8] |
| E/A | 0.95 [0.80–1.8] |
| LAD (mm) | 43.5 [38.0–47.0] |
| LAVI (mL/m2) | 47.0 [34.0–53.0] |
| TRPG (mmHg) | 25.0 [22.0–31.0] |
| RVD (mm) | 27.0 [23.0–31.0] |
| Medications | |
| β-blocker | 18 (66.7) |
| MRA | 8 (33.3) |
| ACEi/ARB | 11 (45.8) |
| ARNI | 0 (0.0) |
| SGLT2 inhibitor | 2 (8.3) |
| Diuretics | 9 (37.5) |
Values are presented as n (%) or as the median [interquartile range]. ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; DCM, dilated cardiomyopathy; eGFR, estimated glomerular filtration rate; HCM, hypertrophic cardiomyopathy; hs-TNT, high-sensitivity troponin T; IVST, interventricular septal thickness; LAD, left atrial diameter; LAVI, left atrial volume index; LVAD, left ventricular assist device; LVDd, left ventricular diastolic dimension; LVDs, left ventricular systolic dimension; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro B-type natriuretic peptide; PWT, posterior wall thickness; RVD, right ventricular dimension; SGLT2, sodium-glucose cotransporter 2; TRPG, tricuspid regurgitation pressure gradient; VT, ventricular tachycardia; WBC, white blood cell count.